Sera Prognostics, INC. (SERA) — SEC Filings

Overview

Sera Prognostics, INC. (SERA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 24, 2026: Sera Prognostics, Inc. filed its Annual Report to Security Holders (ARS) on April 24, 2026, for the period ending December 31, 2025. The filing details the company's operations and financial performance over the past fiscal year. Sera Prognostics, Inc. is a medical laboratory services company incorp

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 27 neutral, 2 mixed. The dominant filing sentiment for Sera Prognostics, INC. is neutral.

Filing Type Overview

Sera Prognostics, INC. (SERA) has filed 1 ARS, 11 8-K, 6 10-Q, 2 DEF 14A, 6 SC 13G/A, 2 SC 13G, 1 10-K with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (29)

• Sera Prognostics Files Annual Report for 2025 — ARS · Apr 24, 2026 Risk: low
  Sera Prognostics, Inc. filed its Annual Report to Security Holders (ARS) on April 24, 2026, for the period ending December 31, 2025. The filing details the comp
• Sera Prognostics Files 8-K: Regulation FD Disclosure — 8-K · Nov 24, 2025 Risk: low
  On November 24, 2025, Sera Prognostics, Inc. filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure and includes finan
• Sera Prognostics Narrows Q3 Loss, Boosts Cash with $53.6M Offering — 10-Q · Nov 13, 2025 Risk: high
  SERA PROGNOSTICS, INC. reported a net loss of $7.814 million for the three months ended September 30, 2025, a slight improvement from the $7.919 million net los
• Sera Prognostics Files 8-K: Regulation FD & Exhibits — 8-K · Sep 5, 2025 Risk: low
  On September 5, 2025, Sera Prognostics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
• Sera Prognostics Narrows Q2 Loss Amidst Strategic Partnerships — 10-Q · Aug 6, 2025 Risk: high
  SERA PROGNOSTICS, INC. reported a net loss of $14.5 million for the three months ended June 30, 2025, a slight improvement from the $15.2 million net loss in th
• Sera Prognostics Files 8-K on Security Holder Vote — 8-K · Jun 5, 2025 Risk: low
  On June 5, 2025, Sera Prognostics, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing does not specify t
• Sera Prognostics Files 8-K with Corporate Updates — 8-K · May 8, 2025 Risk: low
  Sera Prognostics, Inc. filed an 8-K on May 8, 2025, reporting information under Regulation FD and including financial statements and exhibits. The filing detail
• Sera Prognostics Files 10-Q for Q1 2025 — 10-Q · May 7, 2025 Risk: medium
  Sera Prognostics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial position and business operations. Key financial d
• Sera Prognostics Files Definitive Proxy Statement — DEF 14A · Apr 23, 2025 Risk: low
  Sera Prognostics, Inc. filed its definitive proxy statement on April 23, 2025, for its annual meeting on June 5, 2025. The filing outlines the company's governa
• Sera Prognostics Files 8-K on Financials — 8-K · Mar 19, 2025 Risk: low
  On March 19, 2025, Sera Prognostics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as wel
• Sera Prognostics Files 8-K: Material Agreement, Other Events — 8-K · Feb 12, 2025 Risk: medium
  On February 10, 2025, Sera Prognostics, Inc. entered into a material definitive agreement. The company also issued a Regulation FD disclosure and reported other
• Sera Prognostics Files 8-K Report — 8-K · Feb 10, 2025 Risk: low
  On February 10, 2025, Sera Prognostics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" as of Febr
• Sera Prognostics (SERA) Files 8-K — 8-K · Jan 31, 2025 Risk: low
  On January 31, 2025, Sera Prognostics, Inc. (SERA) filed a Form 8-K to report its current status. The filing confirms the company's principal executive offices
• Sera Prognostics Files 8-K Report — 8-K · Jan 13, 2025 Risk: low
  On January 13, 2025, Sera Prognostics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the inclusion of Financial Statement
• Sera Prognostics Files 8-K Report — 8-K · Jan 7, 2025 Risk: low
  On January 6, 2025, Sera Prognostics, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, with the report being filed as of January 7, 20
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Sera Prognostics Files Q3 2024 10-Q — 10-Q · Nov 6, 2024 Risk: medium
  Sera Prognostics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the company
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• Sera Prognostics Files Q2 2024 10-Q Report — 10-Q · Aug 7, 2024 Risk: medium
  Sera Prognostics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, based in Salt Lake City, UT, reported its financial performance for the
• Sera Prognostics Files 8-K on Security Holder Vote — 8-K · Jun 6, 2024 Risk: medium
  On June 6, 2024, Sera Prognostics, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing does not specify t
• SERA PROGNOSTICS, INC. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: low
  SERA PROGNOSTICS, INC. (SERA) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. SERA PROGNOSTICS, INC. filed a 10-Q report on May 8, 2024, for the pe
• Sera Prognostics Announces 2024 Annual Meeting of Stockholders on June 6 — DEF 14A · Apr 23, 2024 Risk: low
  SERA PROGNOSTICS, INC. (SERA) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. The 2024 Annual Meeting of Stockholders for Sera Prognostics, In
• SC 13G Filing — SC 13G · Apr 1, 2024
• Sera Prognostics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 20, 2024 Risk: low
  SERA PROGNOSTICS, INC. (SERA) filed a Annual Report (10-K) with the SEC on March 20, 2024. Sera Prognostics, Inc. filed its annual report on Form 10-K for the f
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Domain Partners VIII Amends Sera Prognostics Stake — SC 13G/A · Jan 26, 2024
  Domain Partners VIII, L.P. filed an amended SC 13G/A on January 26, 2024, indicating a change in their beneficial ownership of Sera Prognostics, Inc. Class A Co
• InterWest Partners X LP Amends Sera Prognostics Stake — SC 13G/A · Jan 19, 2024
  InterWest Partners X LP, a venture capital firm, filed an amended Schedule 13G/A on January 19, 2024, indicating a change in their ownership of Sera Prognostics
• Baker Bros. Advisors LP Discloses Passive Stake in Sera Prognostics — SC 13G · Jan 10, 2024
  Baker Bros. Advisors LP, a New York-based investment firm, filed an SC 13G on January 10, 2024, disclosing its ownership of Sera Prognostics, Inc. common stock
• aMoon Growth Fund Maintains 19.9% Stake in Sera Prognostics — SC 13G/A · Jan 3, 2024
  aMoon Growth Fund Limited Partnership, a Cayman Islands-based entity, filed an amended SC 13G/A on January 3, 2024, disclosing its beneficial ownership in Sera

Risk Profile

Risk Assessment: Of SERA's 21 recent filings, 2 were flagged as high-risk, 5 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Sera Prognostics, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $16K
• Net Income: -$7.814M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: N/A
• Operating Margin: N/A
• Total Assets: $108.125M
• Total Debt: N/A

Industry Context

The prognostics industry, particularly in healthcare and industrial applications, is characterized by rapid technological advancement and significant R&D investment. Companies in this space often face long development cycles and regulatory hurdles before achieving substantial revenue. Competition can be intense, with established players and emerging startups vying for market share.

Top Tags

disclosure (4) · 10-Q (4) · institutional-ownership (4) · SEC Filing (3) · financials (3) · 8-k (3) · amendment (3) · sec-filing (2) · medical-laboratories (2) · filing (2)

Key Numbers

• Period of Report End Date: 2025-12-31 — Indicates the end of the fiscal year covered by the report.
• Filing Date: 2026-04-24 — The date the annual report was officially submitted to the SEC.
• Net Loss (Q3 2025): $7.814M — Slightly improved from $7.919M in Q3 2024
• Net Loss (9M 2025): $24.047M — Slightly improved from $24.319M in 9M 2024
• Revenue (Q3 2025): $16K — Minimal, up from $29K in Q3 2024
• Revenue (9M 2025): $71K — Minimal, up from $53K in 9M 2024
• Public Offering Proceeds: $53.610M — Significant capital raise in February 2025
• Long-term Marketable Securities: $59.080M — Increased from $21.973M at Dec 31, 2024, bolstering liquidity
• Total Assets: $108.125M — Increased from $72.575M at Dec 31, 2024
• Total Stockholders' Equity: $82.182M — Increased from $47.803M at Dec 31, 2024
• Accumulated Deficit: $303.841M — Indicates significant historical losses
• Stock-based Compensation (9M 2025): $4.091M — A significant non-cash operating expense
• Net Loss (Q2 2025): $14.5M — Slight improvement from $15.2M net loss in Q2 2024.
• Net Loss (YTD Q2 2025): $29.7M — Improved from $30.8M net loss in YTD Q2 2024.
• Period End Date: 2025-06-30 — Latest financial reporting period.

Frequently Asked Questions